Enrolment characteristics

Sex (M:F)  54:41  56:49 
Age (y)  67 (1)  68 (1) 
Histological proof of diagnosis  55 (58%)  61 (58%) 
Stage of disease 
II  31 (33%)  40 (39%) 
III  14 (15%)  21 (20%) 
IV  49 (52%)  42 (41%) 
Usual weight (kg)  72.7 (1.2)  74.7 (1.4) 
Pancreatic enzyme supplementation  30 (32%)  29 (28%) 
Baseline characteristics (0 weeks)  Experimental  Control 
Weight at baseline (kg)  60.3 (1.1) (n = 88)  61.4 (1.2) (n = 97) 
Duration of weight loss (weeks)  26.0 (2.1) (n = 88)  25.3 (2.0) (n = 96) 
Rate of weight loss (kg/4 weeks)  2.9 (0.2) (n = 88)  3.2 (0.3) (n = 96) 
% weight loss from usual weight  17.9 (0.9) (n = 88)  17.1 (0.8) (n = 97) 
Body mass index (kg/m^{2})  21.8 (0.4) (n = 88)  22.0 (0.4) (n = 97) 
Lean body mass (kg)  43.3 (0.9) (n = 80)  43.4 (0.9) (n = 91) 
Karnofsky performance score  74.9 (1.2) (n = 88)  73.9 (1.0) (n = 98) 
EQ5D_{index}  0.62 (0.03) (n = 86)  0.62 (0.03) (n = 91) 
EQ5D_{vas}  52.3 (2.2) (n = 87)  57.2 (1.9) (n = 96) 
EORTC QLQC30 global HS  48.8 (2.2) (n = 86)  53.1 (2.2) (n = 95) 
EORTC QLQC30 physical function  64.1 (2.2) (n = 87)  67.7 (2.3) (n = 96) 
Meal intake (kcal/day)  1504 (54) (n = 84)  1613 (51) (n = 95) 
Meal intake (g protein/day)  60 (2) (n = 84)  63 (2) (n = 95) 